ANGO - Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook Stock Soars | Benzinga
Thursday, the FDA granted 510(k) clearance to AngioDynamics Inc’s (NASDAQ:ANGO) AlphaVac F1885 System for pulmonary embolism (PE).
The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.
The indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function.
Also Read: AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement.
In December 2023, AngioDynamics completed patient enrollment in its Acute Pulmonary Embolism Extraction Trial ...